share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5:募資說明書
美股SEC公告 ·  2024/09/09 13:06

Moomoo AI 已提取核心訊息

Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $50,000,000. This update, detailed in a prospectus supplement filed on September 9, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted previous sales limitations under General Instruction I.B.6 of Form S-3. As of the filing date, Allarity Therapeutics has already sold 41,801,224 shares for gross proceeds of $29,998,138. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $50,000,000. This update, detailed in a prospectus supplement filed on September 9, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted previous sales limitations under General Instruction I.B.6 of Form S-3. As of the filing date, Allarity Therapeutics has already sold 41,801,224 shares for gross proceeds of $29,998,138. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc.宣佈與Ascendiant Capital Markets, LLC的銷售協議作出了修訂,增加了其可能提供和出售的普通股總額達到$50,000,000。此次更新詳細說明於2024年9月9日提交的招股書補充中,在2024年5月2日公司的公共流通股票超過$7500萬之後,解除了S-3表格的I.b.6通用說明項下的先前銷售限制。截至提交日,Allarity Therapeutics已經出售了41,801,224股股票,總營業額爲$29,998,138。招股書補充修訂了之前的招股說明書,日期爲2023年11月29日,以及隨後的補充,日期爲2024年3月19日。投資者需要注意,投資Allarity的普通股存在高風險,並應仔細閱讀2024年3月19日的招股書補充和其他參考文件中詳細說明的風險因素。
Allarity Therapeutics Inc.宣佈與Ascendiant Capital Markets, LLC的銷售協議作出了修訂,增加了其可能提供和出售的普通股總額達到$50,000,000。此次更新詳細說明於2024年9月9日提交的招股書補充中,在2024年5月2日公司的公共流通股票超過$7500萬之後,解除了S-3表格的I.b.6通用說明項下的先前銷售限制。截至提交日,Allarity Therapeutics已經出售了41,801,224股股票,總營業額爲$29,998,138。招股書補充修訂了之前的招股說明書,日期爲2023年11月29日,以及隨後的補充,日期爲2024年3月19日。投資者需要注意,投資Allarity的普通股存在高風險,並應仔細閱讀2024年3月19日的招股書補充和其他參考文件中詳細說明的風險因素。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息